Related Experiment Video

Updated: Aug 17, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

TGF-beta inhibitors for the treatment of cancer

Michael Lahn1, Susanne Kloeker, Brandi S Berry

  • 1Eli Lilly & Company Research Laboratories, Therapeutic Area Oncology, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. mlahn@lilly.com

Expert Opinion on Investigational Drugs
|July 12, 2005
PubMed

Insights

Transforming growth factor-beta (TGF-beta) inhibitors are emerging cancer treatments. This review details three inhibitor platforms and assesses their risks and benefits using preclinical and clinical data.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Transforming growth factor-beta (TGF-beta) plays a crucial role in tumorigenesis.
  • Understanding TGF-beta's function has spurred the development of targeted cancer therapies.
  • TGF-beta inhibitors represent a promising therapeutic strategy for various cancers.

Purpose of the Study:

  • To review the current development status of different TGF-beta inhibitor platforms.
  • To assess the risk/benefit profile of TGF-beta inhibitors.
  • To summarize preclinical and clinical data related to TGF-beta inhibition.

Main Methods:

  • Review of scientific literature on TGF-beta inhibitors.
  • Analysis of data from TGF-beta deficiency studies in mice.
  • Summary of non-clinical toxicology studies in rats.
  • Compilation of clinical trial data for monoclonal antibodies targeting TGF-beta.

Main Results:

  • Three main platforms for TGF-beta inhibitors have been developed: antisense oligonucleotides, monoclonal antibodies, and small molecules.
  • Preclinical and clinical data are being gathered to evaluate the efficacy and safety of these inhibitors.
  • TGF-beta deficiency has known effects that inform the risk assessment of inhibitors.

Conclusions:

  • TGF-beta inhibitors are a developing class of anti-cancer therapeutics.
  • Ongoing research and clinical trials are crucial for understanding the full potential and risks of these drugs.
  • A comprehensive risk/benefit assessment is necessary for the clinical application of TGF-beta inhibitors.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...